IndustryCompany release

Bausch Health raises 2026 guidance after Q3 revenue climbs 10% on Xifaxan-led Salix growth

🇺🇸 Bausch Health Companies Inc. (BHC) · Wed 28 Oct 2026

The company reported third-quarter revenue of $2.94 billion, lifted its full-year outlook excluding Bausch + Lomb and announced a $50 million share repurchase programme.

Bausch Health Companies reported consolidated revenue of $2.94 billion for the third quarter of 2026, a 10% increase on the same period a year earlier. GAAP net income attributable to the company was $436 million.

The Salix segment grew 16% in the quarter, and the company attributed this mainly to Xifaxan, whose sales also rose 16%.

On 28 October 2026, Bausch Health raised its full-year guidance for revenue, adjusted EBITDA and adjusted operating cash flow. The upgraded outlook applies to the business excluding Bausch + Lomb. The company also announced a $50 million share repurchase programme.

The summary available does not include the revised guidance ranges, segment-level revenue figures other than the growth rates cited, or details of how the buyback will be executed.

What it means for your team

  • Xifaxan remains the main commercial driver of Salix, so teams tracking the product should note its 16% growth in the quarter.
  • The raised guidance covers the business excluding Bausch + Lomb only, so analysts should keep the two perimeters separate.
  • The specific guidance ranges and buyback terms were not in the information available and should be checked against the company's full results release.

Company's press release (SEC filing): Bausch Health Companies Inc. ↗

Article written by VigiEye from the official source (Bausch Health Companies Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →